1. Scrip
  2. >>Business
  3. >>Strategy

Aldeyra Expects Mid-2025 Refiling Of Reproxalap After Second CRL

 
• By Joseph Haas

Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.

EyeDrops
Aldeyra hopes ongoing trials will provide data finally for FDA approval of reproxalap • Source: Shutterstock

Despite a second complete response letter from the US Food and Drug Administration to its new drug application for reproxalap in dry eye disease, Aldeyra expects to refile for approval during the middle of 2025 and anticipates a six-month review. On a 3 April analyst call, the company noted that the second CRL cited agency concerns about baseline imbalance in ocular discomfort scores in the trial backing the resubmitted NDA.

Key Takeaways
  • Aldeyra’s dry eye candidate reproxalap gets a second FDA complete response, this time expressing concerns about baseline disease states in treatment and vehicle arms of...

Reproxalap, a topical reactive aldehyde species (RASP) modulator, initially was filed for FDA approval in dry eye disease in 2023, backed by four pivotal studies, two each intended to demonstrate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

More from R&D

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.